Kuros Biosciences AG | Finanzwire

Basculer en Français

8295	Companies
114831	Keywords
55272	Articles
62429	Press releases

Home
Companies
Kuros Biosciences AG

BRIEF

published on 11/19/2024 at 07:05, 2 days 3 hours ago

Kuros Biosciences Expands into Extremities Markets

Kuros Biosciences Market Expansion Orthopedic Innovation Extremities Markets MagnetOs Technology
PRESS RELEASE

published on 11/19/2024 at 07:00, 2 days 3 hours ago

Kuros Biosciences Expands into Extremities Markets
Kuros Biosciences expands into extremities markets with strategic appointment of Vice President and Surgeon Advisory Board. Company leverages MagnetOs technology for improved fusion outcomes

Medical Devices Kuros Biosciences Market Expansion Bone Healing Technologies Extremities Markets
BRIEF

published on 10/10/2024 at 07:05, 1 month 11 days ago

Kuros Biosciences Reports Significant Sales Growth and Exceeds Cash Flow Breakeven

Financial Performance Kuros Biosciences Market Expansion MagnetOs Sales Rise Project Fusion
PRESS RELEASE

published on 10/10/2024 at 07:00, 1 month 11 days ago

Kuros reports 149% increase in direct MagnetOs sales and exceeds cash flow breakeven in the first nine months of 2024
Kuros Biosciences reports 149% increase in direct MagnetOs sales and surpasses cash flow breakeven in the first nine months of 2024. Company's financial highlights and future outlook highlighted

Financial Performance Kuros Biosciences MagnetOs Sales Future Outlook Cash Flow Breakeven
BRIEF

published on 08/08/2024 at 07:05, 3 months 13 days ago

Kuros Biosciences Reports First Half of 2024 Results

Clinical Study EBITDA Improvement MagnetOs Sales Growth H1 2024 Results FDA Clearances
PRESS RELEASE

published on 08/08/2024 at 07:00, 3 months 13 days ago

Kuros Biosciences Reports First Half of 2024 Results
Kuros Biosciences reports significant growth in H1 2024, with MagnetOs sales up 159% to CHF 31.6 million. FDA clearances and positive outlook indicate continued success in bone healing technologies market

Sales Growth Kuros Biosciences MagnetOs H1 2024 FDA Clearances
BRIEF

published on 06/25/2024 at 07:05, 4 months 26 days ago

Kuros Biosciences Publishes Superior MAXA Study Outcomes in Spine

Kuros Biosciences MagnetOs Spinal Fusion MAXA Study Autograft
PRESS RELEASE

published on 06/25/2024 at 07:00, 4 months 26 days ago

Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft
Kuros Biosciences announces the publication of MagnetOs MAXA Level 1 study outcomes in Spine, showing superiority over autograft. Study details effectiveness of MagnetOs in posterolateral fusions

Kuros Biosciences MagnetOs MAXA Level 1 Spine Study Bone Healing Technologies
BRIEF

published on 04/24/2024 at 07:05, 6 months 27 days ago

Kuros Biosciences Reports Strong Growth in Q1 2024

FDA 510(k) Clearance Clinical Study Kuros Biosciences Q1 2024 Growth MagnetOs Sales Increase
PRESS RELEASE

published on 04/24/2024 at 07:00, 6 months 27 days ago

Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales
Kuros Biosciences reports strong Q1 2024 performance with 155% increase in direct MagnetOs sales. FDA clearance for MagnetOs Putty and positive EBITDA. Joe Ross appointed SVP Marketing

FDA Clearance Kuros Biosciences MagnetOs Sales Q1 2024 Performance Joe Ross

Accesswire

Published on 11/21/2024 at 10:03, 34 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 37 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 37 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 2 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 12 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 10:04, 32 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 35 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 37 minutes ago

Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 37 minutes ago

Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV
Published on 11/21/2024 at 09:01, 1 hour 36 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy

Les Echos

Published on 11/21/2024 at 06:58, 3 hours 39 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 17 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 16 hours 52 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 16 hours 52 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 2 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE